Leveraging Targeted Flow Cytometry for Faster Pediatric Immunodeficiency Diagnosis

A 20-year cohort published in Frontiers in Immunology is reinforcing what many of us in pediatric immunology already see at the bedside: when we suspect an inborn error of immunity in a child, the weeks and months before a genetic answer arrives are clinically precious, and targeted flow cytometry can be doing far more of the heavy lifting during that window.

The study, drawn from a single center's experience with 243 pediatric patients evaluated between 2005 and 2025, set out to ask a deceptively simple question — how much diagnostic information can a carefully designed flow cytometry panel deliver in children who ultimately receive a molecular confirmation of their IEI?

What the Cohort Shows Us

The clinical presentation landscape was familiar: predominantly antibody deficiencies led the list at 31.7%, followed by syndromic combined immunodeficiencies at 27.1%. Median age at symptom onset was 12 months, while the molecular diagnosis did not arrive until a median of 70 months — a gap that, in real-world management, often determines whether a child reaches transplant, immunoglobulin replacement, or prophylactic antimicrobials in time.

The panel used here was broad and intentional: T-, B-, and NK-cell immunophenotyping, detailed T- and B-cell subset analysis, targeted protein expression assays, and the dihydrorhodamine 123 assay for neutrophil oxidative burst. Abnormal findings appeared in 153 of the 243 children (63%), and in 41 patients — 27% of those with abnormal results — the flow pattern successfully predicted the underlying genetic category.

Where Flow Cytometry Earns Its Place

The diagnostic yield was striking where we most need it. Combined immunodeficiencies reached a 100% yield, and immune dysregulation disorders came in at 82.6% — both significantly higher than the rates seen in syndromic combined immunodeficiencies and antibody deficiencies. Perhaps the most clinically actionable finding for you and your team is the timeline: flow cytometry results preceded molecular confirmation by a median of 12 months, meaning the immune phenotype was guiding management while families were still waiting on sequencing.

For us, this supports a specific management pathway — using targeted FCM as the initial stratification tool, then directing genetic panels based on the functional and protein-expression pattern rather than casting the widest sequencing net first.

Putting This Into Practice

When you are evaluating a child with recurrent infections, autoimmunity, or features suggestive of an IEI, this cohort argues for ordering the targeted flow panel alongside, not after, the genetic workup. The neutrophil oxidative burst test alone can identify chronic granulomatous disease within a day; combined with lymphocyte subset and protein-expression assays, it can narrow the differential well before a gene panel returns.

What we will be watching closely is how these findings translate outside a high-volume pediatric immunology center, and whether other groups can replicate the 100% yield in combined immunodeficiencies in more genetically diverse populations. For now, the message for our daily practice is straightforward: in suspected IEI, a well-designed flow cytometry panel is not a stopgap — it is a clinical compass, and it deserves to be ordered early in the diagnostic cascade.